A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations

NCT05848843 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped 0 participant accrual

Conditions

Lung Cancer
Gastro-intestinal Cancer

Interventions

DRUG: Durvalumab
DRUG: Adagrasib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]